PRO 140 has FDA fast track designation that allows accelerated approval The drug protects healthy cells from HIV infection by binding to CCR5 cellular co-receptor Market for PRO 140 as a single agent therapy projected at about $4 billion annually CYDY recently initiated its first cancer trial in triple negative breast cancer, targeting an unmet […]
The Stocks To Buy Now Blog
Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.